These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33871787)
41. Can therapeutic response to IL-1 blockade confirm the diagnosis of Schnitzler syndrome? Wang C Clin Rheumatol; 2021 Feb; 40(2):805. PubMed ID: 33428102 [No Abstract] [Full Text] [Related]
42. Plasmablastic lymphoma transformation in a patient with Waldenström macroglobulinemia treated with ibrutinib. Castillo JJ; LaMacchia J; Flynn CA; Sarosiek S; Pozdnyakova O; Treon SP Br J Haematol; 2021 Nov; 195(3):466-468. PubMed ID: 34355802 [No Abstract] [Full Text] [Related]
43. Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Krause K; Weller K; Stefaniak R; Wittkowski H; Altrichter S; Siebenhaar F; Zuberbier T; Maurer M Allergy; 2012 Jul; 67(7):943-50. PubMed ID: 22583335 [TBL] [Abstract][Full Text] [Related]
44. Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Asli B; Bienvenu B; Cordoliani F; Brouet JC; Uzunhan Y; Arnulf B; Malphettes M; Rybojad M; Fermand JP Arch Dermatol; 2007 Aug; 143(8):1046-50. PubMed ID: 17709664 [TBL] [Abstract][Full Text] [Related]
45. Complete remission in 3 of 3 anti-IL-6-treated patients with Schnitzler syndrome. Krause K; Feist E; Fiene M; Kallinich T; Maurer M J Allergy Clin Immunol; 2012 Mar; 129(3):848-50. PubMed ID: 22154381 [No Abstract] [Full Text] [Related]
46. Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experience. Lewis KL; Chin CK; Manos K; Casey J; Hamad N; Crawford J; Ho SJ; Issa S; Grigg A; Wood P; Gandhi MK; Do B; Nastoupil L; Hawkes EA; Cheah CY Br J Haematol; 2021 Mar; 192(6):1049-1053. PubMed ID: 32677095 [TBL] [Abstract][Full Text] [Related]
47. Efficacy of interleukin 1 receptor antagonist (anakinra) on a refractory case of Schnitzler's syndrome. Kluger N; Rivière S; Guillot B; Bessis D Acta Derm Venereol; 2008; 88(3):287-8. PubMed ID: 18480937 [No Abstract] [Full Text] [Related]
48. Schnitzler Syndrome With Response to Anakinra Monotherapy: 7 Years of Follow-up. Hidalgo-García Y; García-Fernández E; Palacio-Aller L; Gonzalvo P Actas Dermosifiliogr; 2017 Dec; 108(10):956-958. PubMed ID: 28728792 [No Abstract] [Full Text] [Related]
49. Efficacy and safety of canakinumab treatment in schnitzler syndrome: A systematic literature review. Betrains A; Staels F; Vanderschueren S Semin Arthritis Rheum; 2020 Aug; 50(4):636-642. PubMed ID: 32502728 [TBL] [Abstract][Full Text] [Related]
50. Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation. Innocenti I; Sora F; Autore F; Chiusolo P; Giammarco S; Metafuni E; Bacigalupo A; Sica S; Laurenti L Hematol Oncol; 2021 Apr; 39(2):267-269. PubMed ID: 33150962 [No Abstract] [Full Text] [Related]
51. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997 [TBL] [Abstract][Full Text] [Related]
52. Schnitzler syndrome in a patient with a family history of monoclonal gammopathy. Wilmas K; Aria A; Torres-Cabala CA; Lu H; Duvic M Dermatol Online J; 2018 Jan; 24(1):. PubMed ID: 29469761 [TBL] [Abstract][Full Text] [Related]
53. Successful treatment of Schnitzler syndrome with cyclosporine. Nakajima K; Takahashi M; Yamamoto M; Takahashi A; Sano S; Kodama H; Arima K; Ida H Int J Dermatol; 2014 Jul; 53(7):e361-3. PubMed ID: 24602077 [No Abstract] [Full Text] [Related]
54. The Schnitzler syndrome - a treatment at last? Lipsker D Dermatology; 2002; 205(1):1-2. PubMed ID: 12216542 [No Abstract] [Full Text] [Related]
55. Dermal interleukin-1 expression and effective and long-lasting therapy with interleukin-1 receptor antagonist anakinra in Schnitzler syndrome. Volz T; Wölbing F; Fischer J; Braun M; Maggoschitz I; Schaller M; Berneburg M; Biedermann T Acta Derm Venereol; 2012 Jul; 92(4):393-4. PubMed ID: 22334118 [No Abstract] [Full Text] [Related]
56. Remission of Schnitzler syndrome after treatment with anakinra. Frischmeyer-Guerrerio PA; Rachamalla R; Saini SS Ann Allergy Asthma Immunol; 2008 Jun; 100(6):617-9. PubMed ID: 18592830 [No Abstract] [Full Text] [Related]
57. Treatment patterns and outcomes among mantle cell lymphoma patients treated with ibrutinib in the United States: a retrospective electronic medical record database and chart review study. Sharman J; Kabadi SM; Clark J; Andorsky D Br J Haematol; 2021 Feb; 192(4):737-746. PubMed ID: 33095453 [TBL] [Abstract][Full Text] [Related]
58. Schnitzler syndrome. Soubrier M Joint Bone Spine; 2008 May; 75(3):263-6. PubMed ID: 18378180 [TBL] [Abstract][Full Text] [Related]
59. Schnitzler syndrome: a case report of successful treatment using the anti-CD20 monoclonal antibody rituximab. Ramadan KM; Eswedi HA; El-Agnaf MR Br J Dermatol; 2007 May; 156(5):1072-4. PubMed ID: 17355230 [No Abstract] [Full Text] [Related]
60. Complete remission of Schnitzler syndrome and Waldenström macroglobulinemia under rituximab-cyclophosphamide-dexamethasone. Aouba A; Pressiat C; Pricopi M; Georgin-Lavialle S; Boue F; Lievre-Castilla MA; Marfaing-Koka A; Prevot S; Decottignies A Dermatology; 2015; 230(1):18-22. PubMed ID: 25471063 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]